Patient P-01709

Synthetic patientNBL-101 · Day 113 · 35–44 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Improving

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Declining

Discontinuation risk

64%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 58 ME-01 recommended — Monitoring Escalation ME-01
Day 59 GI-04 recommended — GI Support Protocol GI-04
Day 59 Patient accepted — Started ME-01 in the companion
Day 60 Patient accepted — Started GI-04 in the companion
Day 62 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 68 GI symptom burden −19% vs expected — GI Support Protocol GI-04
Day 74 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

Nutritional resilience-7
Inflammatory activity-6
Toxicity-6
Treatment adherence+2

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Monitoring Escalation ME-01Day 58
Result: deterioration detected before clinical escalation
GI Support Protocol GI-04Day 59
Result: symptom burden −19%

LIFE OS recommendation

Clinician Review CR-01

82%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

53.3/100

stable · -1.8 vs previous 14 d

Toxicity

Blood

36.8/100

improving · -9.8 vs previous 14 d

Sleep quality

Wearable

43.2/100

improving · +2.9 vs previous 14 d

Energy level

Daily log

4/10

improving · +0.5 vs previous 14 d

Stress level

Daily log

6.4/10

improving · -0.4 vs previous 14 d

Steps

Wearable

1,486

stable · -2 vs previous 14 d

Adherence

Companion

49.5 %

worsening · -2.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 32 from the failing basin, 56 from restoration.

Would help

CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 70%

Would not help

NP-02 Dietary Support Protocol
already tried, no meaningful change
Keep fat low
GI +4 next day on high-intake days · n 18
Keep simple carbs low
GI +4 next day on high-intake days · n 17
Keep spicy low
GI +3.9 next day on high-intake days · n 21

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4detractor · 95%
Simple carbohydrates
+4detractor · 95%
Spicy / capsaicin
+3.9detractor · 95%
Histamine load
+3.6detractor · 95%
Alcohol
+2.6detractor · 83%
Insoluble fibre
+0.6no signal · 17%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 47
- WearableHRV 28 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 36/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 77 bpm
- Wearable1,486 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.5 · butyrate capacity 36/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 25 ms
Sleep: 7.1 h
Steps: 1,950
Resting HR: 78 bpm

Daily log: GI score 53, nutritional resilience 43, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01386	21%	S13	—	—	70
P-01352	21%	S20	—	—	70
P-01699	27%	S04	GI-04	improved	69
P-01508	22%	S18	—	—	68
P-01509	22%	S17	—	—	68
P-01875	22%	S11	—	—	67
P-01817	22%	S14	—	—	67
P-01877	27%	S01	CR-01	improved	67
P-01629	23%	S19	—	—	66
P-01714	27%	S14	GI-04	improved	66
P-01858	31%	S14	NP-02	improved	65
P-01317	23%	S19	—	—	65